Type 2 diabetes trials in China

In China 192 Also abroad 1245

154 of 192 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Where
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huizhou, Jiangmen, Jinan, Jining, Jinzhou, Lanzhou, Lishui, Luoyang, Macau, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Pingxiang, Qinhuangdao, Shanghai, Shenyang, Siping, Suzhou, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xiangyang, Xianyang, Xuancheng, Xuzhou, Yinchuan, Zhenjiang, Zibo
Age
18 years and over
People
11,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00
Phase 3Taking people
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Where
Shenzhen
Age
18 years and over
People
2,539
Run by
Hudson Biotech
See details and how to joinNCT07481747
Phase 3Not yet taking people in China
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Where
Chongqing, Jinan, Nanjing, Tianjin, Zhenjiang
Age
18 years and over
People
200 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07931495 · EU 2026-525470-18-00
Phase 3Not yet taking people in China
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
Where
Changde, Changzhou, Chengdu, Chongqing, Hefei, Hengshui, Huizhou, Huzhou, Jilin City, Jinan, Kaifeng, Luoyang, Nanjing, Nanyang, Shanghai, Shenzhen, Shijiazhuang, Tianjin, Zhenjiang
Age
18 years and over
People
450 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00
Phase 3Not yet taking people in China
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Where
Beijing, Changde, Changzhou, Chongqing, Hengshui, Jinan, Kaifeng, Langfang, Luoyang, Nanjing, Shantou, Shijiazhuang, Suzhou, Xining, Zhengzhou, Zhenjiang
Age
18 years and over
People
1,060 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07931599 · EU 2026-525474-20-00
Phase 4Taking people
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Where
Shanghai
Age
18 years to 70 years
People
820
Run by
Huijie Zhang
See details and how to joinNCT07775846
Phase 2Not yet taking people in China
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
Where
Beijing
Age
18 years to 70 years
People
150
Run by
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT07929350
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Beijing, Changchun, Hefei, Herbin, Huizhou, Jinan, Langfang, Luoyang, Nanjing, Pingxiang, Shanghai, Suzhou, Xianyang, Zhenjiang
Age
18 years and over
People
2,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Where
Beijing, Cangzhou, Changchun, Hefei, Herbin, Huizhou, Jinan, Kaifeng, Langfang, Luoyang, Nanjing, Ningbo, Pingxiang, Shanghai, Siping, Suzhou, Wuxi, Xi'an, Xianyang, Xuzhou, Yueyang, Zhenjiang
Age
18 years and over
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Where
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi, Jincheng, Jinzhou Shi, Langfang, Luoyang, Meihekou, Nanjing, Nanyang, Shanghai, Shantou, Shenyang, Shijiazhuang, Wuhan, Wuhu, Xianyang, Xuzhou, Yan’an, Yueyang, Zhumadian, Zibo
Age
18 years and over
People
351 worldwide
Run by
AstraZeneca
See details and how to joinNCT07775404
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Where
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00
Phase 3Not yet taking people in China
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Where
Nanjing, Shanghai
Age
18 years and over
People
450
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07920939
Phase 3Not yet taking people in China
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Where
Beijing, Bozhou, Cangzhou, Changzhou, Chongqing, Daqing, Ganzhou, Guangzhou, Jiaxing, Jinan, Liuzhou, Luoyang, Luzhou, Sanya, Shanghai, Shenyang, Shiyan, Suzhou, Wuhan, Xi'an, Xuancheng, Yuncheng, Zhengzhou
Age
18 years and over
People
330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07922330
Phase 2Not yet taking people in China
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Where
Beijing
Age
18 years and over
People
364
Run by
Shenzhen Salubris Pharmaceuticals Co., Ltd.
See details and how to joinNCT07923357
Phase 3Taking people
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Where
Beijing, Changchun, Hefei, Herbin, Huai'an, Huzhou, Jinan, Langfang, Luoyang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Xianyang, Zhengzhou, Zibo
Age
18 years and over
People
300
Run by
Hoffmann-La Roche
See details and how to joinNCT07670416
Phase 2Not yet taking people in China
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention
Where
Beijing
Age
18 years to 70 years
People
150
Run by
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT07920640
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Where
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing, Shanghai, Tianjin, Zigong
Age
18 years and over
People
1,035 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Where
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou, Jinan, Luoyang Shi, Luzhou, Nanchang, Nanjing, Ningbo, Shanghai, Wenzhou, Wuhan, Xianyang
Age
18 years and over
People
900 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00
Phase 4Taking people
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
Where
Chongqing, Hefei, Taiyuan, Wenzhou
Age
18 years to 65 years
People
285
Run by
The First Affiliated Hospital of Anhui Medical University
See details and how to joinNCT07697391
Phase 3Taking people
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Where
Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, Tianjin
Age
18 years and over
People
1,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00
Phase 3Not yet taking people in China
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang, Luzhou, Nanchang, Nanjing, Nanyang, Ningbo, Qinhuangdao Shi, Shanghai, Shijiazhuang, Suzhou, Xianyang
Age
18 years and over
People
2,115 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00
Phase 3Not yet taking people in China
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Liaoyou, Luoyang Shi, Nanjing, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Xuzhou, Yibin, Zigong
Age
45 years to 64 years
People
3,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00
Phase 3Not yet taking people in China
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Where
Shanghai, Shenzhen
Age
18 years and over
People
680
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07913061
Phase 1/2Not yet taking people in China
cfMSC Therapy for Diabetes
Where
Shenzhen
Age
18 years to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT07495956
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Where
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng, Hangzhou, Hefei, Huai'an, Jinan, Jincheng, Jining, Jinzhou Shi, Kaifeng, Langfang, Liangyugang, Luoyang, Meihekou, Nanjing, Nantong, Nanyang, Pinggu, Pingxiang, Sanya, Shanghai, Shantou, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuhu, Xi'an, Xiangyang, Xianyang, Xuzhou, Yan’an, Yueyang, Zhumadian, Zibo
Age
18 years and over
People
2,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00